Skip to main content

FDA: Veozah, First Hormone-Free Hot Flash Drug, Issued Black Box Warning

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 18, 2024.

By India Edwards HealthDay Reporter

WEDNESDAY, Dec. 18, 2024 -- The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot flashes in menopausal women, due to rare but potentially severe liver risks.

In new communication issued Dec. 17, the FDA advised that women taking Veozah should undergo regular blood testing to monitor liver health.

Warning signs of liver injury can include fatigue, nausea, vomiting, dark urine, light-colored stool, or yellowing of the skin or eyes, a news release says.

Patients experiencing these symptoms should immediately stop taking the medication and consult with their doctor.

“It’s important to note that the overall benefit-risk of Veozah has not changed and remains positive, but we want to further ensure that patients and healthcare providers are aware of the potential side effects,” as well as recommended lab testing, Astellas Pharma, the manufacturer of the drug, said in a statement.

Veozah was approved in 2023. At the time, it was the first non-hormonal prescription option for treating hot flashes.

The medication works by blocking neurokinin B, a receptor involved in the brain’s regulation of body temperature.

Since its approval, the drug's popularity has grown steadily, with nearly 29,000 prescriptions filled in May 2024 alone, according to FDA data.

The FDA’s heightened warning comes after reviewing a recent case where a patient developed elevated liver markers after taking Veozah for about 40 days.

The patient’s symptoms resolved, and liver function normalized after stopping the medication.

To minimize risk, the FDA recommends monthly blood tests for liver markers during the first three months of Veozah treatment and follow-up tests at months six and nine.

Because medication effects can vary widely due to health, genetics, and other factors, the FDA emphasized that it is difficult to predict who might develop liver issues.

Sources

  • U.S. Food and Drug Administration (FDA), release, Dec. 16 2024
  • CNN, report, Dec. 17, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted December 2024

Read this next

Early Menopause Might Mean Greater Age-Related Brain Decline

WEDNESDAY, April 23, 2025 -- Early menopause could be a warning sign for future age-related brain decline, a new study says. Women who entered menopause before 40 had a greater...

New Trial Will Test Gene-Edited Pig Liver for Sudden Liver Failure Patients

WEDNESDAY, April 16, 2025 -- A new clinical trial will soon test if a pig liver can help people whose own livers have suddenly stopped working. The hope? That animal organs can...

Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.